Bluebird bags breakthrough status for CALD gene therapy – PMLiVE
PMLiVE |
Bluebird bags breakthrough status for CALD gene therapy
PMLiVE Bluebird Bio has claimed an FDA breakthrough designation for its Lenti-D gene therapy for cerebral adrenoleukodystrophy (CALD) – a rare neurological disease mainly affecting young males. The new status – which could result in a speedy review by the US … bluebird's Lenti-D Gets Breakthrough Therapy Status From FDA FDA 'Breakthrough' status for tafamidis and Lenti-D |
